Synergistic Activities of Moxifloxacin Combined with Piperacillin-Tazobactam or Cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii Clinical Isolates

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 1055-1057

  Jung, Rose ^a   Husain, Maroof ^a   Choi, Michael K ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG POTENTIATION; ENTEROBACTER CLOACAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME KILL METHOD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; ENZYME INHIBITORS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; QUINOLINES;

EID: 1442349053     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.1055-1057.2004     Document Type: Article

References (8)

1. Anonymous. 1999. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
2. Balfour, J. A., and L. R. Wiseman. 1999. Moyifloxacin. Drugs 57:363-374.
3. Bayer Corporation. 2001. Avelox and Avelox I.V. (moxifloxacin) prescribing information. Bayer Corporation, West Haven, Conn.
4. Bergogne-Berezin, E., and J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.
5. Fass, R. J. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob. Agents Chemother. 41:1818-1824.
6. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
7. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
8. National Committee for Clinical. Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.